219 related articles for article (PubMed ID: 1987737)
1. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
Perez DJ; Harvey VJ; Robinson BA; Atkinson CH; Dady PJ; Kirk AR; Evans BD; Chapman PJ
J Clin Oncol; 1991 Dec; 9(12):2148-52. PubMed ID: 1960557
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
[TBL] [Abstract][Full Text] [Related]
7. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
9. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
Beretta G; Locatelli C; Tabiadon D; Labianca R; Fraschini P; Luporini G
Oncology; 1987; 44(1):6-12. PubMed ID: 2436124
[TBL] [Abstract][Full Text] [Related]
13. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
Martoni A; Tomasi L; Farabegoli G; Giovannini M; Monetti N; Ganzina F; Pannuti F
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):11-7. PubMed ID: 6581974
[TBL] [Abstract][Full Text] [Related]
18. [Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
Yayoi E; Furukawa J; Takatsuka Y; Kobayashi T; Aikawa T; Maeura Y; Kaji M; Kotsuma Y
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1621-4. PubMed ID: 1530320
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.
Dittrich C; Baur M; Mader R; Schlappack O; Dudczak R; Leitha T; Lenzhofer R; Hoffmann S; Vieder L; Heberle U
Am J Clin Oncol; 1990; 13 Suppl 1():S29-39. PubMed ID: 1963274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
